Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides

DSpace/Manakin Repository

Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides

Citable link to this page

 

 
Title: Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides
Author: Birsoy, Kıvanç; Possemato, Richard; Lorbeer, Franziska K.; Bayraktar, Erol C.; Thiru, Prathapan; Yucel, Burcu; Wang, Tim; Chen, Walter W.; Clish, Clary B.; Sabatini, David M.

Note: Order does not necessarily reflect citation order of authors.

Citation: Birsoy, Kıvanç, Richard Possemato, Franziska K. Lorbeer, Erol C. Bayraktar, Prathapan Thiru, Burcu Yucel, Tim Wang, Walter W. Chen, Clary B. Clish, and David M. Sabatini. 2014. “Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides.” Nature 508 (7494): 108-112. doi:10.1038/nature13110. http://dx.doi.org/10.1038/nature13110.
Full Text & Related Files:
Abstract: As the concentrations of highly consumed nutrients, particularly glucose, are generally lower in tumours than in normal tissues1,2, cancer cells must adapt their metabolism to the tumour microenvironment. A better understanding of these adaptations might reveal cancer cell liabilities that can be exploited for therapeutic benefit. Here, we developed a continuous flow culture apparatus (Nutrostat) for maintaining proliferating cells in low nutrient media for long periods of time and used it to undertake competitive proliferation assays on a pooled collection of barcoded cancer cell lines cultured in low glucose conditions. Sensitivity to low glucose varies amongst cell lines, and an RNAi screen pinpointed mitochondrial oxidative phosphorylation (OXPHOS) as the major pathway required for optimal proliferation in low glucose. We found that cell lines most sensitive to low glucose are defective in the upregulation of OXPHOS normally caused by glucose limitation as a result of either mtDNA mutations in Complex I genes or impaired glucose utilization. These defects predict sensitivity to biguanides, anti-diabetic drugs that inhibit OXPHOS3,4, when cancer cells are grown in low glucose or as tumour xenografts. Remarkably, the biguanide sensitivity of cancer cells with mtDNA mutations was reversed by ectopic expression of yeast NDI1, a ubiquinone oxidoreductase that allows bypass of Complex I function5. Thus, we conclude that mtDNA mutations and impaired glucose utilization are potential biomarkers for identifying tumours with increased sensitivity to OXPHOS inhibitors.
Published Version: doi:10.1038/nature13110
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4012432/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:13347592
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters